Antibiotic therapy for ventilator-associated tracheobronchitis: A standard of care to reduce pneumonia, morbidity and costs?

Current Opinion in Pulmonary Medicine

Volumn 21, Issue 3, 2015, Pages 250-259

  Craven, Donald E ^a,b   Hudcova, Jana ^a,b   Rashid, Jawad ^a,b  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aerosolized antibiotics; Bacterial pathogens; Early appropriate therapy; Improved patient outcomes; Intravenous antibiotics; Length of ICU stay; Multidrug resistant; Prevention; Ventilator days; Ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; HEALTH CARE COST; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; PATHOGENESIS; REVIEW; RISK FACTOR; TRACHEOBRONCHITIS; VENTILATOR ASSOCIATED PNEUMONIA; VENTILATOR ASSOCIATED TRACHEOBRONCHITIS; BRONCHITIS; ECONOMICS; PATHOLOGY; PNEUMONIA, VENTILATOR-ASSOCIATED; TRACHEITIS;

ANTI-BACTERIAL AGENTS; BRONCHITIS; HUMANS; MORBIDITY; PNEUMONIA, VENTILATOR-ASSOCIATED; TRACHEITIS;

EID: 84926331541     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000158     Document Type: Review

References (48)

1. Nseir S, Di Pompeo C, Pronnier P, et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J 2002; 20:1483-1489.
2. Nseir S, Favory R, Jozefowicz E, et al. Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study. Crit Care 2008; 12:R62.
3. Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008; 36:2008-2013.
4. Agrafiotis M, Siempos II, Falagas ME. Frequency, prevention, outcome and treatment of ventilator-associated tracheobronchitis: systematic review and meta-analysis. Respir Med 2010; 104:325-336.
5. Nseir S, Ader F, Marquette CH. Nosocomial tracheobronchitis. Curr Opin Infect Dis 2009; 22:148-153.
6. Nseir S, Martin-Loeches I, Makris D, et al. Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia. Crit Care 2014; 18:R129.
7. Craven DE, Lei Y, Ruthazer R, et al. Incidence and outcomes of ventilatorassociated tracheobronchitis and pneumonia.Am J Med 2013; 126:542-549.
8. Craven DE, Hudcova J, Craven KA, et al. Antibiotic treatment of ventilator-associated tracheobronchitis: to treat or not to treat? Curr Opin Crit Care 2014; 20:532-541.
9. Craven DE, Chroneou A, Zias N, Hjalmarson KI. Ventilator-associated tra-cheobronchitis: the impact of targeted antibiotic therapy on patient outcomes. Chest 2009; 135:521-528.
10. Craven DE, Hjalmarson KI. Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. Clin Infect Dis 2010; 51 (Suppl 1):S59-66.
11. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Thoracic Documents, approved by the ATS, Borad of Directors and the IDSA Guideline Committee. Am J Respir Crit Care Med 2005; 171:388-416.
12. Muscedere JG, Shorr AF, Jiang X, et al., Canadian Critical Care Trials G. The adequacy of timely empiric antibiotic therapy for ventilator-associated pneu-monia:an important determinantof outcome.J Crit Care 2012; 27:322; e7-14.
13. Unroe M, Kahn JM, Carson SS, et al. One-year trajectories of care and resource utilization for recipients of prolonged mechanical ventilation: a cohort study. Ann Intern Med 2010; 153:167-175.
14. Pandharipande PP, Girard TD, Jackson JC, et al. Long-term cognitive impairment after critical illness. N Engl J Med 2013; 369:1306-1316.
15. Dallas J, Skrupky L, Abebe N, et al. Ventilator-associated tracheobronchitis in a mixed surgical and medical ICU population. Chest 2011; 139:513-518.
16. Nseir S, Di Pompeo C, Soubrier S, et al. Outcomes of ventilated COPD patients with nosocomial tracheobronchitis: a case-control study. Infection 2004; 32:210-216.
17. Nseir S, Di Pompeo C, Soubrier S, et al. Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory failure: a case-control study. Crit Care 2005; 9:R238-R245.
18. Simpson VS, Bailey A, Higgerson RA, Christie LM. Ventilator-associated tracheobronchitis in a mixed medical/surgical pediatric ICU. Chest 2013; 144:32-38.
19. Karvouniaris M, Makris D, Manoulakas E, et al. Ventilator-associated tracheobronchitis increases the length of intensive care unit stay. Infect Control Hosp Epidemiol 2013; 34:800-808.
20. Safdar N, Crnich CJ, Maki DG. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respir Care 2005; 50:725-739.
21. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
22. Grgurich PE, Hudcova J, Lei Y, et al. Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens. Expert review of respiratory medicine 2012; 6:533-555.
23. Palmer LB, Smaldone GC. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med 2014; 189:1225-1233.
24. Kollef MH, Hamilton CW, Montgomery AB. Aerosolized antibiotics: do they add to the treatment of pneumonia? Curr Opin Infect Dis 2013; 26:538-544.
25. Stulik L, Malafa S, Hudcova J, et al. Alpha-hemolysin activity of methicillin-susceptible Staphylococcus aureus predicts ventilator-associated pneumonia. Am J Respir Crit Care Med 2014; 190:1139-1148.
26. Wunderink RG. Clinical criteria in the diagnosis of ventilator-associated pneumonia. Chest 2000; 117 (4 Suppl 2):191S-194S.
27. el-Ebiary M, Torres A, Gonzalez J, et al. Quantitative cultures of endotracheal aspirates for the diagnosis of ventilator-associated pneumonia. Am Rev Respir Dis 1993; 148 (6 Pt 1): 1552-1557.
28. Micek ST, Heuring TJ, Hollands JM, et al. Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy 2006; 26:204-213.
29. Bouza E, Granda MJ, Hortal J, et al. Preemptive broad-spectrum treatment for ventilator-associated pneumonia in high-risk patients. Intensive Care Med 2013; 39:1547-1555.
30. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621-629.
31. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, et al. Acineto-bacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31:649-655.
32. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333-1341.
33. Tasbakan MS, Pullukcu H, Ekren PK, et al. Colistin use in ventilator-associated pneumonia due to panresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Mikrobiyol Bul 2009; 43:61-70.
34. Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combinationofcolistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013; 141: 1214-1222.
35. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia dueto Pseudomonas aeruginosa. Chest 1996; 109:1019-1029.
36. Planquette B, Timsit JF, Misset BY, et al. Pseudomonas aeruginosa ventilator-associated pneumonia. predictive factors of treatment failure. Am J Respir Crit Care Med 2013; 188:69-76.
37. Nseir S, Deplanque X, Di Pompeo C, et al. Risk factors for relapse of ventilator-associated pneumonia related to nonfermenting Gram negative bacilli: a case-control study. J Infect 2008; 56:319-325.
38. Palmer LB. Ventilator-associated infection. Curr Opin Pulm Med 2009; 15:230-235.
39. Lu Q, Yang J, Liu Z, et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia causedby Pseudomonas aeruginosa.Am JRespir Crit Care Med 2011; 184:106-115.
40. Rouby JJ, Bouhemad B, Monsel A, et al. Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies. Anesthesiology 2012; 117:1364-1380.
41. Niederman MS, Chastre J, Corkery K, et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012; 38:263-271.
42. Montgomery AB, Vallance S, Abuan T, et al. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow inline nebulizer system in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv 2014; 27:441-448.
43. Craven DE. Ventilator-associated tracheobronchitis (VAT): questions, answers, and a new paradigm? Crit Care 2008; 12:157.
44. Abu-Salah T, Dhand R. Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update. Adv Ther 2011; 28:728-747.
45. Lipovy B, Rihova H, Gregorova N, et al. Epidemiology of ventilator-associated tracheobronchitis and vantilator-associated pneumonia in patients with inhalation injury at the Burn Centre in Brno (Czech Republic). Ann Burns Fire Disasters 2011; 24:120-125.
46. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596.
47. Herridge M, Cameron JI. Disability after critical illness. N Engl J Med 2013; 369:1367-1369.
48. Kass EH. Bacteriuria and the diagnosis of infections of the urinary tract; with observations on the use of methionine as a urinary antiseptic. AMA Arch Intern Med 1957; 100:709-714.